The global antifungal agents market is anticipated to grow at a considerable CAGR of nearly 3.5% during the forecast period (2021-2027). The factor contributing to the growth of antifungal agents include the rise in the number of COVID-19 cases and diabetic patients. Moreover, due to COVID-19, there is an increase in the number of viral infections and bacteria’s which is causing fungal infections, and patients are at high risk of healthcare-associated infections including candidemia or bloodstream infections caused by Candida. Diabetic patients are at more risk of getting affected by black fungus infection which is also known as Mucormycosis.
To Request a Sample of our Report on Antifungal Agents Market: https://www.omrglobal.com/request-sample/antifungal-agents-market
In addition, the companies are strategically increasing their product portfolios to grow in the market. For instance, in April 2021, Pfizer acquired Amplyx Pharmaceuticals, Inc. which is a privately-held company working in the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Fosmnaogepix (APX001) is Amplyx lead compound and is a novel asset that is under development for the treatment of invasive fungal infections. Accordingly, infectious disease is responsible for more than 8.4 million mortalities annually, globally.
Furthermore, In January 2019, Mayne Pharma Group Ltd. launched TOLSURA (SUBa – itraconazole) 65 mg capsule in the US. TOLSURA is a formulation of itraconazole for the treatment of fungal infection including blastomycosis, histoplasmosis, and aspergillosis. These infections commonly occur in immunocompromised patients such as patients with a history of cancer, transplants, and HIV/AIDS. The company received approval for TOLSURA in 2021, from the US Food and Drug Administration (FDA). Additionally, in November 2019, SCYNEXIS, Inc. developed Ibrexafungerp for the treatment of Candida Auris and other difficult-to-treat fungal infections. Thus, the mergers & acquisitions, partnerships and collaborations and new and innovative product development in the antifungal agents are driving the growth of the market during the forecast period.
Market Coverage
· The market number available for – 2020-2027
· Base year- 2020
· Forecast period- 2021-2027
Ø Segment Covered-
· By Drug Class
· By Dosage Type
· By Route of Administration
Ø Regions Covered–
· North America
· Europe
· Asia-Pacific
· Rest of the World
Ø Competitive Landscape-
Key questions addressed by the report
· What is the market growth rate?
· Which segment and region dominate the market in the base year?
· Which segment and region will project the fastest growth in the market?
· How COVID-19 impacted the market?
· Deviation from the pre-COVID-19 forecast
· Most affected region and segment
· Who is the leader in the market?
· How players are addressing challenges to sustain growth?
· Where is the investment opportunity?
(Get 15% Discount on Buying this Report)
A full Report Antifungal Agents Market is Available at: https://www.omrglobal.com/industry-reports/antifungal-agents-market
Global Antifungal Agents Market Segmentation
By Drug Class
· Polyene
· Echinocandins
· Allylamines
· Azole
By Drug Dosage
· Powder
· Ointment
· Drugs
By Route of Administration
· Parenteral
· Topical
· Oral
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
